This was when the share price was in the 40c range and over 200m(?) fully diluted shares on issue (not sure what the options prices were).
I am not a long term investor- I am a short termer. I see value in short term potential, such as the fact that the product may never make profits, but along the way there will be various value-adding announcements.
If they can change the prototype modelling, get a Chinese third party on board (which they have) then if claw back a small percentage of where the market cap was back in 2006, there will be value added for current shareholders.
This above doesn't take into account the new therapeutic company acquisition which adds a totally different dimension to SBN but reflects their focus of close-to-commercialisation products.
IMO reviving the Oraline product is definitely worth a shot.
SBN Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held